Dr. Gulshan Abbas, the sister of staunch international Uyghur advocate, Rushan Abbas, remains detained in a Chinese prison. U.S. Senators Marco Rubio (R-FL), Dick Durbin (D-IL), and colleagues released a joint statement ahead of the six-year anniversary of Dr....
News
Latest News
ICYMI: Rubio Reviews “Made in China 2025” Nine Years Later
“Made in China 2025” initiative, nearing Beijing’s target, threatens U.S. U.S. Senator Marco Rubio (R-FL) September 10, 2024 Washington Post …[I]n May 2015, Beijing went public with a 10-year plan to dominate high-value, high-technology sectors…. [W]ith the decade...
Rubio Releases Report: “The World China Made: ‘Made in China 2025’ Nine Years Later”
U.S. Senator Marco Rubio (R-FL) released a report titled “The World China Made: ‘Made in China 2025’ Nine Years Later,” which reviews the successes and failures of Communist China’s “Made in China 2025” industrial policy. It is the sequel to Rubio’s 2019 report titled...
Next Week: Rubio Staff Hosts Mobile Office Hours
U.S. Senator Marco Rubio’s (R-FL) office will host in-person Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of Senator Rubio’s...
ICYMI: Rubio: Biden-Harris Economy Leaves Men Behind
Biden-Harris Economy Is Leaving Men Behind U.S. Senator Marco Rubio (R-FL) September 6, 2024 Fox News Hidden in the shadows and forgotten: That’s the only way to describe the state of male employment in this country. The percentage of men aged 25-54 who report working...
Rubio, Cruz, Scott to Blinken: America is Being Left Vulnerable to the Cuban Regime
Recently, the Biden-Harris Administration implemented an expansion of nonimmigrant visas (NIV) to Cubans. Allowing the Cuban regime to benefit from visas is yet another move this administration has made to appease the Cuban dictatorship. This also puts our nation at...
ICYMI: Rubio Release Coronavirus Plan to Combat Supply Chain Risk, U.S. Dependence on China
My Coronavirus Plan: Combating America’s supply chain risk and dependence on China for pharmaceuticals
By U.S. Senator Marco Rubio (R-FL)
February 27, 2020
Medium
Across the world, news of the coronavirus outbreak is dominating headlines, and with good reason – the pandemic’s apparently high transmissibility rates and lethal danger it poses make it an exceptionally grave threat. The fact that China, ground zero for the virus and home to an overwhelming majority of ongoing cases, refuses to be transparent with its data adds to the seriousness of the situation.
As I wrote recently in an op-ed, the Chinese Communist Party is not a responsible global power, and the party’s blatant mishandling of the coronavirus has clearly revealed that.
Unfortunately, this was predictable.
Last year, I noted in Modern Healthcare that when it comes to the threat China poses to the U.S. healthcare industry, we cannot afford to be complacent.
And a report I released last February detailed critical vulnerabilities in America’s medical supply chain, warning, “the U.S. runs the risk of losing important components of its medical supply chain to China’s government-backed industry.”
At the time, those seemed like abstract concerns, but we now know they are real. Americans unable to buy medical masks and who see headlines about potential shortages of critical, irreplaceable drugs will be familiar.
The coronavirus outbreak makes clear how dependent our nation is on China for industrial capacity, especially in critical areas of our economy.
Health and Human Services Secretary Azar publicly acknowledged this on Tuesday when he confirmed to me that the coronavirus outbreak is “a wake-up call that perhaps we are overly dependent on a supply chain so heavily concentrated in one place in the world.”
That’s why I am planning to introduce legislation to curb America’s dependence on China that will:
- REQUIRE drugmakers to provide the Food and Drug Administration (FDA) with the volume of active pharmaceutical ingredients (API) derived from each manufacturing source,
- RESTORE Buy American Act preferences for pharmaceuticals, and
- COMBAT supply chain risk and U.S. dependence on China for APIs.